Why did MTNB's EPS remain unchanged in Q3 2024?

The EPS of Matinas Biopharma (MTNB) in Q3 2024 remained unchanged at -$0.85 compared to the previous quarter. This stability in EPS can be attributed to several factors: |code|Ticker|Name|Date|Diluted EPS YoY|Diluted EPS|market_code| |---|---|---|---|---|---|---| |MTNB|MTNB.A|Matinas Biopharma|2024 Q1|0|-0.03|170| |MTNB|MTNB.A|Matinas Biopharma|2024 Q2|33.33333333333333|-0.02|170| |MTNB|MTNB.A|Matinas Biopharma|2024 Q3|38.84892086330935|-0.85|170| 1. **Strategic Focus on Asset Monetization**: Matinas Biopharma is exploring options to increase its value, including potentially monetizing assets like MAT2203, its lead Phase 3 ready antifungal drug candidate. This strategic focus could indicate a deliberate approach to maintain financial stability rather than making significant changes that would alter the EPS. 2. **Financial Conservation**: The company believes its cash position is sufficient to fund planned operations through the third quarter of 2024, despite a reported revenue decline and net loss. This financial conservatism might imply that the company is not introducing significant new initiatives that could affect profitability, thus maintaining EPS stability. In conclusion, the consistent EPS in Q3 2024 reflects Matinas Biopharma's strategic focus on asset monetization and financial conservation, which have helped maintain profitability despite challenging market conditions.